strattera- atomoxetine hydrochloride capsule
carilion materials management - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine 10 mg - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of
strattera- atomoxetine hydrochloride capsule
carilion materials management - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of
strattera- atomoxetine hydrochloride capsule
carilion materials management - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of
strattera- atomoxetine hydrochloride capsule
carilion materials management - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of
strattera capsule
eli lilly canada inc - atomoxetine (atomoxetine hydrochloride) - capsule - 25mg - atomoxetine (atomoxetine hydrochloride) 25mg - miscellaneous central nervous system agents
strattera 25 mg gélule
lilly s.a espagne - atomoxetine - gélule - 25 mg - systeme nerveux - psychoanaleptiques - strattera est indiqué dans le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah) chez les enfants de 6 ans et plus et chez les adolescents dans le cadre d'une prise en charge thérapeutique globale. le traitement doit être initié par un spécialiste dans le traitement du tdah comme un pédiatre, un pédopsychiatre ou un psychiatre. le diagnostic doit être établi selon les critères actuels du dsm ou de l'icd.
strattera
eli lilly nederland b.v. - atomoksetinas - kietosios kapsulės - 40 mg; 25 mg; 18 mg; 10 mg; 60 mg - atomoxetine
strattera 25 mg
eli lilly Čr, s.r.o., Česká republika - atomoxetín - 78 - sympathomimetica
strattera 10mg tvrdá tobolka
eli lilly Čr, s.r.o., praha array - 17338 atomoxetin-hydrochlorid - tvrdá tobolka - 10mg - atomoxetin
strattera 100mg tvrdá tobolka
eli lilly Čr, s.r.o., praha array - 17338 atomoxetin-hydrochlorid - tvrdá tobolka - 100mg - atomoxetin